文献速递肾癌与肾肿瘤

透明细胞肾细胞癌的基因组学:系统综述与荟萃分析

Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2022-01-03

该系统综述与荟萃分析纳入93篇文献、14696例患者、14299份原发肿瘤样本和969份转移样本,评估透明细胞肾细胞癌基因突变与拷贝数变异的总体及亚组患病率,并比较原发灶与转移灶。转移灶中10个基因的突变患病率显著高于原发灶,VHL突变患病率由原发灶64%升至转移灶75%(p < 0.001)。作者结论强调对肾癌转移灶优先活检以全面探索转移性疾病生物学、服务于治疗目的的价值。

要点

  • 转移灶中10个基因的突变患病率显著高于原发灶,研究间异质性无或很小。
  • VHL突变患病率从原发灶64%显著升至转移灶75%(p < 0.001)。
  • CDKN2A(p16)位于9p21.3,在76%的转移样本中缺失。

核心结论

  • 作者结论认为,结果强调了对肾癌转移灶优先活检以全面探索转移性疾病生物学、服务于治疗目的的价值。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline和Embase数据库,检索算法为(「肾肿瘤」[Mesh] 或 「肾细胞癌」)且(「基因组学」[Mesh] 或 「突变」),检索时间为1999年1月至2021年2月,按PRISMA声明进行批判性综述,最终纳入93篇文献。
  • 荟萃分析共纳入14696例患者、14299份原发肿瘤样本和969份转移样本。

主要发现

  • 转移灶中10个基因的突变患病率显著高于原发灶,研究间异质性无或很小。
  • VHL突变患病率从原发灶64%显著升至转移灶75%(p < 0.001)。
  • 从原发灶到转移灶,染色体1p36.11、9p21.3和18的缺失患病率显著增加,染色体1q21.3、7q36.3、8q和20q11.21的获得患病率显著增加。
  • CDKN2A(又称p16,参与细胞周期进程)位于9p21.3位点,在76%的转移样本中缺失。
  • ASXL1位于20p11.21,在50%的转移性肾细胞癌中扩增,而原发肿瘤中为21%(p < 0.001),与BAP1功能密切相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although antiangiogenic treatments and immunotherapies have significantly improved the prognosis of metastatic renal cell carcinoma (RCC), many patients will develop resistance, leading to treatment failure. Genetic tumor heterogeneity is a major cause of this resistance. OBJECTIVE: To perform a meta-analysis of genomic data for clear-cell RCC obtained from primary tumors and metastases to assess the prevalence of gene mutations and copy number alterations (CNAs). EVIDENCE ACQUISITION: Articles were selected from Medline and Embase libraries using the search algorithm ("Kidney Neoplasms"[Mesh] OR "Renal Cell Carcinoma") AND ("Genomics"[Mesh] OR "Mutation") from January 1999 to February 2021. A critical review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. Ninety-three publications were selected for inclusion in this meta-analysis. EVIDENCE SYNTHESIS: Our meta-analysis included a total 14 696 patients, 14 299 primary tumor samples, and 969 metastatic samples. We evaluated the overall and subgroup prevalence of gene mutations and CNAs, including comparisons between primary tumors and metastases. In particular, for metastases we observed that the mutation prevalence was significantly more marked for ten genes compared to primary tumors, with no or little heterogeneity across studies. The VHL mutation prevalence increased significantly from 64% in primary tumors to 75% in metastases (p < 0.001). There was a significant increase in CNA prevalence from primary tumors to metastases for chromosomes 1p36.11, 9p21.3, and 18 in terms of losses, and for chromosomes 1q21.3, 7q36.3, 8q, and 20q11.21 in terms of gains. CDKN2A, also called p16 and involved in cell-cycle progression, is located at the 9p21.3 locus and was lost in 76% of metastatic samples. ASXL1, located on 20p11.21 and amplified in 50% of metastatic RCCs compared to 21% of primary tumors (p < 0.001), is closely linked to BAP1 function. CONCLUSIONS: Our results underline the added value of preferential biopsies on RCC metastases to fully explore the biology of metastatic disease for therapeutic purposes. PATIENT SUMMARY: We reviewed the literature on genetic mutations in primary tumors and metastatic lesions in kidney cancer. Our pooled results for all the relevant studies show a higher level of mutations in metastases than in primary tumors. This highlights the importance of taking biopsies of metastases to analyze genetic mutations and potentially guide selection of the most suitable treatment strategy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bui TO, Dao VT, Nguyen VT, et al. Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. Eur Urol. 2022. PMID: 34991918. doi:10.1016/j.eururo.2021.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。